WaveMan
WaveMan · Company
WVE · Wave Life Sciences, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

WVE Wave Life Sciences (WVE) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001631574
Quote by TradingView
Form 144 · 2
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
150
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $41.8K priced

What the filings say about WVE

Insiders, 180 days
-$135.1K net sold
4 sellers · 0% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$106.6K
2 notices

Wave Life Sciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Wave Life Sciences, Inc. insiders sold a net $135.1K of stock across 92 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Rawcliffe Adrian
Director
SELL
2026-08-13 SECtraded 2026-08-12
12,700
$67.2K
-36.2%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 8, 2025.
  • 3 other insiders sold within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Rawcliffe Adrian sold about $67.2K of WVE on Aug 12, 2026; 3 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.
Wagner Heidi L
Director
SELL
2026-08-13 SECtraded 2026-08-11
7,000
$42.1K
-36.2%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Dec 8, 2025.
  • The trade is 15.6% of the 44,930 shares held after it.
  • 3 other insiders sold within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Wagner Heidi L sold about $42.1K of WVE on Aug 11, 2026; 3 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.
TAKANASHI KEN
Director
SELL
2026-08-13 SECtraded 2026-08-11
3,864
$23.2K
-36.2%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Aug 5, 2025.
  • The trade is 19.2% of the 20,079 shares held after it.
  • 3 other insiders sold within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director TAKANASHI KEN sold about $23.2K of WVE on Aug 11, 2026; 3 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.
Tan Aik Na
Director
SELL
2026-08-13 SECtraded 2026-08-11
432
$2.6K
-36.2%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on Dec 8, 2025.
  • The trade is 1.7% of the 24,968 shares held after it.
  • 3 other insiders sold within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Tan Aik Na sold about $2.6K of WVE on Aug 11, 2026; 3 other insiders sold within 30 days and 150 funds added in the latest 13F quarter.
RA CAPITAL MANAGEMENT, L.P.
Director
BUY
2026-03-30 SEC
971,091
$6.3M
-52.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Mar 27, 2026.
  • +29.7% median (+37.2% mean) 90-day return after 4 previous buys.
  • The trade is 3.6% of the 26,975,505 shares held after it.
  • No other insider bought within 30 days.
  • 150 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director RA CAPITAL MANAGEMENT, L.P. bought about $6.3M of WVE on Mar 30, 2026; 150 funds added in the latest 13F quarter.
92 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 87 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$135.1K over 180 days
-$135.1K over 90 days
more than 53% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
150 funds bought in last quarter
more than 81% of Pharma & Biotech
Revenue
-60.5% year over year
below 83% of Pharma & Biotech
Margin
-478.3% net margin
below 77% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
22.4% of the float short (float per yahoo 2026-10-27) · 6.5 days to cover · settled 2026-10-15
more than 75% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch WVE

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-51.1%12M
-56%+30%+116%+202%2025-102025-122026-022026-042026-062026-082026-10 2026-03-26 · RA CAPITAL MANAGEMENT, L.P. bought $30.0M2025-12-11 · GSK plc bought $27.9M2026-03-27 · RA CAPITAL MANAGEMENT, L.P. bought $16.0M2026-03-30 · RA CAPITAL MANAGEMENT, L.P. bought $6.3M2026-03-26 · RA CAPITAL MANAGEMENT, L.P. bought $2.2M2025-12-08 · Francis Chris sold $1.7M2025-12-08 · Francis Chris sold $1.6M2025-12-09 · Moran Kyle sold $1.0M2025-12-08 · Moran Kyle sold $900.0K2025-12-08 · Francis Chris sold $800.0K2025-12-08 · Moran Kyle sold $792.0K2025-12-08 · Moran Kyle sold $750.0K2025-12-08 · Francis Chris sold $665.3K2025-12-08 · Moran Kyle sold $660.0K2025-12-08 · Rawcliffe Adrian sold $630.0K2025-12-08 · HENRY CHRISTIAN O sold $540.6K2025-12-08 · HENRY CHRISTIAN O sold $535.5K2025-12-08 · Francis Chris sold $528.0K2025-12-08 · Francis Chris sold $407.8K2025-12-08 · Tan Aik Na sold $375.0K2025-12-08 · Francis Chris sold $316.8K2026-02-26 · Francis Chris sold $270.1K2025-12-08 · Francis Chris sold $268.5K2025-12-08 · Tan Aik Na sold $267.8K2025-12-08 · Tan Aik Na sold $258.4K2025-12-08 · Tan Aik Na sold $255.0K2026-02-26 · Francis Chris sold $229.4K2025-12-08 · HENRY CHRISTIAN O sold $211.1K2025-12-08 · Tan Aik Na sold $191.2K2025-12-08 · Verdine Gregory L. sold $157.3K2026-02-09 · BOLNO PAUL sold $141.0K2025-12-08 · Francis Chris sold $140.6K2026-01-02 · Francis Chris sold $128.6K2025-12-08 · CORRIGAN MARK sold $125.7K2025-12-08 · Tan Aik Na sold $112.4K2025-12-08 · Verdine Gregory L. sold $112.1K2025-11-13 · Rawcliffe Adrian sold $109.4K2025-12-08 · Wagner Heidi L sold $98.0K2025-12-08 · Tan Aik Na sold $95.5K2025-12-08 · CORRIGAN MARK sold $91.7K2025-12-08 · Wagner Heidi L sold $91.0K2025-12-08 · HENRY CHRISTIAN O sold $82.2K2026-08-12 · ADRIAN G RAWCLIFFE filed to sell $64.1K2026-08-11 · HEIDI L WAGNER filed to sell $42.5K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns WVE: institutional holders (13F)

13F holdings, latest reported quarter
RA CAPITAL MANAGEMENT, L.P.
26,975,505 sh
$156.7M
BlackRock, Inc.
19,202,461 sh
$111.6M
GSK plc
18,245,691 sh
$106.0M
MAVERICK CAPITAL LTD
10,278,115 sh
$59.7M
Driehaus Capital Management LLC
5,443,143 sh
$31.6M

Congress trades in WVE

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

WVE planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
ADRIAN G RAWCLIFFE
Filed 2026-08-12
$64.1K
HEIDI L WAGNER
Filed 2026-08-11
$42.5K

WVE mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
PROFUND VP PHARMACEUTICALS
$175.0K position · as of 2026-06-30
1.5%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$228.7K position · as of 2026-07-31
1.1%
Global X Genomics & Biotechnology ETF
$574.2K position · as of 2026-05-31
1.0%
NORTH SQUARE DYNAMIC SMALL CAP FUND
$4.7M position · as of 2026-05-31
0.6%
AlphaCentric Life Sciences and Healthcare Fund
$207.2K position · as of 2026-06-30
0.4%
Driehaus Small Cap Growth Fund
$4.3M position · as of 2026-06-30
0.3%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Paul Bolno
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$12.3M
$18.6M
$3.2M
+116%
-34%
2024
$4.3M
$17.4M
$1.8M
+57%
-63%
2023
$3.9M
$2.2M
$1.7M
-36%
-57%
2022
$2.7M
$6.1M
$1.2M
-11%
-52%
2021
$3.9M
$1.3M
$1.5M
-60%
-23%
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $135.1K sold by insiders over 180 days, 150 funds added last quarter, $106.6K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

WVE financials

Revenue growth
-60.5%
XBRL, annual
Net margin
-478.3%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$193.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-68.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-50.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-64.8%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-28.4%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$42.7M$108.3M$113.3M$3.6M
Operating income-$215.4M-$110.4M-$68.0M-$162.7M
Net income-$204.4M-$97.0M-$57.5M-$161.8M
EPS (diluted)-1.21-0.70-0.54-2.05
Operating cash flow-$187.5M-$151.0M-$19.4M-$127.8M
Cash$602.1M$302.1M$200.4M$88.5M
SEC XBRL, fiscal years, as known on 2026-10-28

WVE Stock Sonar score 5/7 axes

Find similar shapesCompare

WVE ranks highest on institutional and government (81st percentile) and risk and compliance (50th), and lowest on growth (17th), among Pharma & Biotech peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
42
Inputs
  • Return on equity-68.3% · 43 pct, sector of 545
  • Return on assets-50.0% · 44 pct, sector of 691
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-64.8% · 38 pct, sector of 576
Growth
17
Inputs
  • Revenue growth, YoY-60.5% · 17 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
25
Inputs
  • Net Form 4 buying (codes P and S), 180d-$135K · 51 pct, sector of 429
  • Insider buyers, 180d0 · 0 pct, sector of 438
Institutional and government
81
Inputs
  • Funds adding, latest quarter150 · 81 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
50
Inputs
  • Short interest, % of float+22.4% · 11 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+3.5% · 90 pct, sector of 511
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

WVE filings, in plain words

Are Wave Life Sciences insiders buying or selling WVE?

In the 180 days to 2026-10-28, Wave Life Sciences insiders were net sellers, a net $135.1K across purchases and sales reported on Form 4, by 4 sellers.

Are there planned insider sales of WVE?

Yes. 2 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $106.6K of stock; the latest, by ADRIAN G RAWCLIFFE, was filed 2026-08-12.

Read the full summary

In the 180 days to 2026-10-28, Wave Life Sciences insiders were net sellers of WVE, a net $135.1K across purchases and sales reported on Form 4 by 4 sellers. None of the 4 insider sales was flagged as made under a Rule 10b5-1 plan. Insiders filed 2 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $106.6K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies